Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lima, André Bacellar Costa ^a,b   Macedo, Ligia T ^a,b   Sasse, André Deeke ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Centro de Evidências em Oncologia CEVON   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BLEEDING; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; META ANALYSIS; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; LUNG TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 79960992697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022681     Document Type: Review

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59 (4): 225-49.
2. Chen F, Cole P, Bina WF, (2007) Time trend and geographic patterns of lung adenocarcinoma in the United States, 1973-2002. Cancer Epidemiol Biomarkers Prev 16 (12): 2724-9.
3. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (7010): 899-909.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2): 92-8.
5. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, et al. (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19 (2): 432-41.
6. Ferrara N, Hillan KJ, Gerber HP, Novotny W, (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (5): 391-400.
7. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (11): 2184-91.
8. Cohen MH, Gootenberg J, Keegan P, Pazdur R, (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12 (6): 713-8.
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (24): 2542-50.
10. Sandler AB, Johnson DH, Brahmer J, Schiller JH, Ostland M, et al. (2006) Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24 (18): 381s-s.
11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 (8): 1227-34.
12. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21 (9): 1804-9.
13. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 17 (24): 2815-34.
14. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
15. Sterne JAC, Egger M, Smith GD, (2001) Investigating and dealing with publication and other biases. In: Egger M, Smith GD, Altman DG, Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: Metaanalisys in context. 2nd ed London BMJ Publication Group.
16. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7 (3): 177-88.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327 (7414): 557-60.
18. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol Feb 11;[Epub ahead of print].
19. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, et al. (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25 (30): 4743-50.
20. Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, et al. (2009) Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. J Clin Oncol 27 (15s): abstr 8036.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6 (7): e1000097.
22. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, et al. (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14 (3): 263-73.
23. Ranpura V, Hapani S, Wu S, (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305 (5): 487-94.
24. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, et al. (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26 (1): 60-5.
25. Garrido P, Thatcher N, Crino L, Dansin E, Laskin J, et al. (2009) Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390). Ejc Suppl 7 (2): 557-.
26. Gressett SM, Shah SR, (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43 (3): 490-501.
27. van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC, (2007) Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25 (21): 2993-5.
28. Hood JD, Meininger CJ, Ziche M, Granger HJ, (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274 (3 Pt 2): H1054-8.
29. Mourad JJ, des Guetz G, Debbabi H, Levy BI, (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19 (5): 927-34.
30. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH, (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28 (6): 949-54.
31. Thatcher N, Tsai CM, Laskin J, Crino L, Pavlakis N, et al. (2009) MO19390 (SAiL): hypertension in patients with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC) receiving first-line bevacizumab plus chemotherapy. J Thorac Oncol 4 (9): S358-S9.
32. Tsai C, Griesinger F, Laskin J, Crino L, Pavlakis N, et al. (2009) Low incidence of grade 3 bleeding events and low discontinuation rates associated with firstline bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study. Ejc Suppl 7 (2): 557-8.
33. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, et al. (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11 (8): 733-40.
34. Lynch T, Jahanzeb M, Kosty M, Robles R, Wozniak A, et al. (2008) Clinical Outcomes for Non-Small Cell Lung Cancer (Nsclc) from the Aries Study: A Bevacizumab (Bv) Treatment Observational Cohort Study (Ocs). Annals of Oncology 19: 93-.
35. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, et al. (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16 (1): 269-78.